Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma

Inclusion Criteria: * For the dose escalation cohorts, histologically-proven metastatic colorectal adenocarcinoma that is refractory to 2 prior standard treatment regimens or standard treatment was declined. * For the dose expansion cohorts, histologically-proven metastatic colorectal adenocarcinoma that is refractory to 1 prior standard treatment regimen or standard therapy was declined. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy of at least 12 weeks * Measurable disease * Intolerance to at least 2 prior standard therapy regimens * Acceptable laboratory parameters * Adult (≥18 years old) Exclusion Criteria: * Known brain metastasis * Any prior history of or suspected current autoimmune disorders (with the exception of vitiligo, resolved childhood atopic dermatitis, prior Grave's disease) * Prior history of allogeneic bone marrow, stem-cell, or solid organ transplantation * Prior treatment with checkpoint inhibitors and other immunotherapy treatments, including anti-LAG-3, anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibodies, if less than 5 half lives before study drug administration * Prior history of Grade 3 or greater drug-related diarrhea/colitis during treatment with checkpoint inhibitors or other immunotherapy treatments. * Treatment with any local or systemic anti-neoplastic therapy or any other investigational agent in the 4 weeks prior to study drug administration * Require, at the time of study entry, treatment with steroids \> 10 mg/day of oral prednisone (or equivalent), except topical use, steroid inhaler, nasal spray or ophthalmic solution * History of clinically significant cardiovascular disease, gastrointestinal disorder, or significant pulmonary compromise. * Second primary malignancy that has not been in remission for greater than 3 years, with the exception of non-melanoma skin cancer, cervical carcinoma in situ,or squamous intraepithelial lesion on PAP smear, localized prostate cancer (Gleason score \<6), or resected melanoma in situ.